stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Operating cash flow
ImmunityBio, Inc.'s operating cash flow for fiscal 2025 was −$304.9M, compared with −$391.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$281.1M. Over the past ten years it has ranged from −$391.2M (fiscal 2024) to −$25.3M (fiscal 2015); the current reading is higher than 36% of that period. ImmunityBio, Inc. ranks 566th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$304.9M | — |
| FY2024 | −$391.2M | — |
| FY2023 | −$366.8M | — |
| FY2022 | −$337.5M | — |
| FY2021 | −$274.4M | — |
| FY2020 | −$171.7M | — |
| FY2019 | −$152.1M | — |
| FY2018 | −$63.4M | — |
| FY2017 | −$48.8M | — |
| FY2016 | −$38.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$66.5M | — |
| Mar 2026 | −$75.4M | — |
| Dec 2025 | −$70.4M | — |
| Sep 2025 | −$68.9M | — |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $323.9M |
| PTGX Protagonist Therapeutics, Inc. compare | $131.2M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.9M |
| TWST Twist Bioscience Corporation compare | −$53.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$157.0M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. | −$281.1M |
| CYTK Cytokinetics, Incorporated compare | −$572.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement